Transient disruption of attentional performance following escalating amphetamine administration in rats. 2004

Robyn L Kondrad, and Joshua A Burk
Department of Psychology, College of William and Mary, Williamsburg, VA 23187, USA.

BACKGROUND Attentional deficits are thought to be critically involved in the development of positive symptoms in schizophrenia. The present experiment tests the general hypothesis that sensitization of the mesolimbic dopaminergic system contributes to the attentional deficits in schizophrenia. OBJECTIVE The present study assessed attentional performance following administration of an escalating amphetamine regimen and subsequent "challenge" amphetamine administration in rats. METHODS Rats were trained to perform a two-lever sustained attention task that involved discrimination of visual signals and no signal presentation. After reaching criterion, subjects were assigned to receive escalating amphetamine or saline. Attentional performance was assessed immediately following escalating amphetamine, following "challenge" amphetamine administration (1.0 mg/kg) to amphetamine-pretreated rats, and for 3 days after the challenge session. At the end of this experiment, a dose-response study was conducted with saline-pretreated rats to confirm the appropriateness of the challenge dose. RESULTS Amphetamine-pretreated animals demonstrated a transient increase in errors on nonsignal trials following escalating amphetamine administration. The latency to press a lever was decreased during and after challenge amphetamine administration. Administration of 1.0 mg/kg amphetamine did not alter accuracy of amphetamine-pretreated animals or of saline-pretreated animals in the dose-response experiment. CONCLUSIONS Prior escalating amphetamine administration transiently disrupted attention, increasing incorrect "claims" for a signal on trials when no signal was presented. The present data support the existing literature that escalating amphetamine regimens may be useful to model the attentional deficits that contribute to the psychotic symptoms in schizophrenia.

UI MeSH Term Description Entries
D008297 Male Males
D011597 Psychomotor Performance The coordination of a sensory or ideational (cognitive) process and a motor activity. Perceptual Motor Performance,Sensory Motor Performance,Visual Motor Coordination,Coordination, Visual Motor,Coordinations, Visual Motor,Motor Coordination, Visual,Motor Coordinations, Visual,Motor Performance, Perceptual,Motor Performance, Sensory,Motor Performances, Perceptual,Motor Performances, Sensory,Perceptual Motor Performances,Performance, Perceptual Motor,Performance, Psychomotor,Performance, Sensory Motor,Performances, Perceptual Motor,Performances, Psychomotor,Performances, Sensory Motor,Psychomotor Performances,Sensory Motor Performances,Visual Motor Coordinations
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000661 Amphetamine A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE. Desoxynorephedrin,Levoamphetamine,Phenopromin,l-Amphetamine,Amfetamine,Amphetamine Sulfate,Amphetamine Sulfate (2:1),Centramina,Fenamine,Mydrial,Phenamine,Thyramine,levo-Amphetamine,Sulfate, Amphetamine,l Amphetamine,levo Amphetamine
D000697 Central Nervous System Stimulants A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. Analeptic,Analeptic Agent,Analeptic Drug,Analeptics,CNS Stimulant,CNS Stimulants,Central Nervous System Stimulant,Central Stimulant,Analeptic Agents,Analeptic Drugs,Central Stimulants,Agent, Analeptic,Agents, Analeptic,Drug, Analeptic,Drugs, Analeptic,Stimulant, CNS,Stimulant, Central,Stimulants, CNS,Stimulants, Central
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001288 Attention Focusing on certain aspects of current experience to the exclusion of others. It is the act of heeding or taking notice or concentrating. Focus of Attention,Selective Attention,Social Attention,Attention Focus,Attention, Selective,Attention, Social,Selective Attentions
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D020318 Rats, Long-Evans An outbred strain of rats developed in 1915 by crossing several Wistar Institute white females with a wild gray male. Inbred strains have been derived from this original outbred strain, including Long-Evans cinnamon rats (RATS, INBRED LEC) and Otsuka-Long-Evans-Tokushima Fatty rats (RATS, INBRED OLETF), which are models for Wilson's disease and non-insulin dependent diabetes mellitus, respectively. Long-Evans Rat,Long Evans Rats,Evans Rats, Long,Long Evans Rat,Long-Evans Rats,Rat, Long-Evans,Rats, Long Evans

Related Publications

Robyn L Kondrad, and Joshua A Burk
March 2005, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Robyn L Kondrad, and Joshua A Burk
March 2005, Behavioural brain research,
Robyn L Kondrad, and Joshua A Burk
October 1979, Life sciences,
Robyn L Kondrad, and Joshua A Burk
January 1994, Drug metabolism and disposition: the biological fate of chemicals,
Robyn L Kondrad, and Joshua A Burk
January 1984, Stroke,
Robyn L Kondrad, and Joshua A Burk
December 2018, Molecular imaging and biology,
Robyn L Kondrad, and Joshua A Burk
September 1982, Pharmacology, biochemistry, and behavior,
Copied contents to your clipboard!